Lithium is an essential trace mineral that has been used as a treatment for bipolar disorder (manic-depressive illness) for over 70 years and that remains one of the most effective and most extensively studied treatments in all of psychiatry. Lithium is unique among the mood stabilisers — it is the only treatment that has been consistently shown to reduce the risk of suicide in bipolar patients (by approximately 80% compared to untreated bipolar disorder, one of the most dramatic suicide risk reductions of any treatment in psychiatry), and it is one of the few treatments that addresses both the manic and the depressive poles of bipolar disorder simultaneously. The mechanism of lithium action is multi-faceted and involves the modulation of multiple second messenger systems in neurons, the regulation of gene expression through the GSK-3 beta pathway, the enhancement of neurotrophic factor production (particularly BDNF, brain-derived neurotrophic factor), and the stabilisation of neuronal membrane potentials through effects on sodium channels. This multi-target mechanism explains why lithium is effective in a broad range of psychiatric conditions beyond bipolar disorder — including major depressive disorder (as an augmentation agent), schizoaffective disorder, aggression, and cluster headache.
The GSK-3 Beta Pathway
The most well-characterised mechanism of lithium action is through the inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) — an enzyme that phosphorylates and inactivates multiple substrates that are critical for neuronal survival, synaptic plasticity, and circadian rhythm regulation. GSK-3 beta phosphorylates the transcription factor cAMP response element-binding protein (CREB) on Ser129, inhibiting its transcriptional activity and reducing the expression of the neurotrophic factors and anti-apoptotic proteins that CREB induces. Lithium inhibits GSK-3 beta directly (by competing with the magnesium ion that is required for GSK-3 beta activity) and indirectly (by increasing the phosphorylation of GSK-3 beta on Ser9, which inhibits GSK-3 beta activity through an allosteric mechanism). The net effect of GSK-3 beta inhibition is increased CREB activity, increased expression of neurotrophic factors and anti-apoptotic proteins, enhanced synaptic plasticity, and improved neuronal survival under conditions of stress and metabolic challenge.
The clinical significance of GSK-3 beta inhibition extends beyond its direct effects on neurons. GSK-3 beta is also a key regulator of the circadian clock — it phosphorylates the PERIOD proteins that are the core components of the molecular circadian oscillator in the suprachiasmatic nucleus,调节 the timing of the circadian rhythm. Lithium lengthens the circadian period (delays the phase of the circadian rhythm), which may explain its efficacy in bipolar patients with circadian rhythm disturbances (a common feature of bipolar disorder, where sleep deprivation and circadian disruption can precipitate manic and depressive episodes). GSK-3 beta is also involved in the regulation of dopamine and serotonin neurotransmission — lithium-induced GSK-3 beta inhibition is associated with increased dopamine turnover in the prefrontal cortex and with increased serotonin receptor sensitivity, both of which are consistent with the mood-stabilising and anti-manic effects of lithium.
Lithium and Suicide Prevention
Lithium is the only treatment in psychiatry that has been consistently shown to reduce the risk of suicide in bipolar patients. A meta-analysis of 22 studies in bipolar patients found that lithium treatment was associated with an approximately 80% reduction in the risk of suicide and attempted suicide compared to untreated bipolar disorder or to treatment with other mood stabilisers (carbamazepine, valproate). This dramatic suicide risk reduction is one of the most compelling arguments for the use of lithium as a first-line treatment in bipolar disorder, particularly in patients with a history of suicidal ideation or attempts. The mechanism of lithium suicide prevention is not fully characterised but is thought to involve the combined effects of lithium on impulsivity (lithium reduces impulsivity in bipolar patients, which is a major determinant of suicidal behaviour), on aggression (lithium has well-documented anti-aggressive effects in both bipolar and non-bipolar populations), and on the underlying neurobiology of suicide (lithium increases 5-HT and dopamine turnover and reduces the HPA axis hyperactivity that is associated with suicidal behaviour).
Practical Application
For bipolar disorder, the evidence-based dose is 600-1,200mg of lithium carbonate daily (or the equivalent dose of lithium citrate), divided into 2-3 doses and titrated to achieve a serum lithium level of 0.6-1.0mmol/L (the standard therapeutic range). Serum lithium levels must be monitored regularly (initially weekly, then monthly once stable) because the narrow therapeutic window (the toxic level is approximately 1.5-2.0mmol/L, only slightly above the therapeutic range) means that dehydration, renal impairment, or drug interactions that reduce lithium clearance can precipitate lithium toxicity. The most common adverse effects of lithium are tremor (which can be reduced by using the extended-release formulation or by lowering the dose), weight gain, hypothyroidism (due to the lithium-induced impairment of thyroid hormone synthesis), and polyuria (due to lithium-induced nephrogenic diabetes insipidus, which responds to amiloride). For comprehensive bipolar management, lithium pairs well with the antipsychotic medications (for acute mania or psychosis), with lamotrigine (for bipolar depression), and with the omega-3 fatty acids (which have demonstrated efficacy as adjunctive therapy in bipolar disorder).
Leave a Reply